NCT03866980View on ClinicalTrials.gov

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

PHASE3TerminatedINTERVENTIONAL

Enrollment

164

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions

Lung Cancer Non-small Cell Stage IV

Interventions

BIOLOGICAL

AK105

IV infusion

DRUG

carboplatin

IV infusion

DRUG

pemetrexed

IV infusion

DRUG

placebo

IV infusion

DRUG

Anlotinib

PO

Trial Locations (2)

100853

Chinese PLA General Hospital, Beijing

200025

Shanghai Chest Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Akeso Tiancheng, Inc

OTHER

lead

Akeso

INDUSTRY